Intellectual Property

AmProtein has revolutionized protein manufacture through use of two important proprietary systems:

  1. Non-sparging, novel O2 transfer method, resulting in commercialization of single-use, plastic bag-based bioreactors and paper carrier-based perfusion system.
  2. The discovery of a DNA physical structure-based expression mechanism common to eukaryotic cells, known as 'the GC-rich method.

By taking advantage of the above discoveries, AmProtein has developed tissue-targeted Enbrel and two-domain protein therapeutics with improved efficacies and longer half-lives for unmet medical needs.

AmProtein owns all of the below published patent applications and granted patents: